Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

This study tests a combination of three drugs — pembrolizumab (immunotherapy), chemotherapy, and lenvatinib (a targeted drug) — as a first-line treatment for malignant pleural mesothelioma, a rare and aggressive cancer of the lining of the lungs usually linked to asbestos exposure. **You may be eligible if...** - You have been diagnosed with advanced or metastatic malignant pleural mesothelioma that cannot be removed by surgery - You have not yet received any treatment for mesothelioma - Your oxygen levels at rest are 94% or above without supplemental oxygen - You have at least one tumor that can be measured on a scan - Your expected survival is more than 90 days **You may NOT be eligible if...** - You have already received treatment for mesothelioma - You have serious other illnesses, uncontrolled infections, or autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.